Moderna’s Covid-19 vaccine candidate shows 94.5% efficacy in phase 3 COVE study

Moderna’s Covid-19 vaccine candidate has demonstrated significant efficacy in phase 3 COVE study. (Credit: Liz Masoner from Pixabay)